Santhera Pharmaceuticals Holding AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SPHDF research report →
About the company
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases.
- CEO
- Dario Eklund
- IPO
- 2014
- Employees
- 78
- HQ
- Pratteln, NSW, CH
Price Chart
- Market Cap
- $344.83M
- P/E
- -3.87
- P/S
- 2.84
- P/B
- -16.78
- EV/EBITDA
- -9.62
- Div Yield
- 0.00%
- Gross Margin
- 18.74%
- Op Margin
- -48.99%
- Net Margin
- -63.79%
- ROE
- 684.83%
- ROIC
- -37.53%
- Revenue
- $77.22M · 97.41%
- Net Income
- $-49,259,603 · -17.36%
- EPS
- $-3.78 · -2.44%
- Op Income
- $-37,834,129
- FCF YoY
- 2.37%
- 52W High
- $23.25
- 52W Low
- $12.28
- 50D MA
- $23.16
- 200D MA
- $17.71
- Beta
- -0.27
- Avg Volume
- 104
Get TickerSpark's AI analysis on SPHDF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our SPHDF coverage
Recent articles, reports, and earnings notes.
No research on SPHDF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SPHDF report →Similar companies
Peers in the same neighborhood.